Pharma major Lupin has announced the launch of its Clobetasol Propionate Lotion 0.05% having received an approval from the United States Food and Drug Administration (FDA) earlier.

Lupin’s Clobetasol Propionate Lotion 0.05% is the generic equivalent of Galderma Labs’ Clobex® lotion. It is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses, in patients 18 years of age or older.

Clobetasol Propionate Lotion 0.05% had annual sales of approximately USD 12.6 million in the US (IQVIA MAT December 2017).

Lupin is currently developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.

The Company is the 4th largest pharmaceutical player in the US by prescriptions (Quintiles IMS MAT March 2017); 2nd largest Indian pharmaceutical company by global revenues (March 31st, 2017, Bloomberg); 6th largest generic pharmaceutical player in Japan and 6th largest company in Indian Pharmaceutical Market (Quintiles IMS MAT June 2017).